Project/Area Number |
23K20915
|
Project/Area Number (Other) |
21H01253 (2021-2023)
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Multi-year Fund (2024) Single-year Grants (2021-2023) |
Section | 一般 |
Review Section |
Basic Section 19010:Fluid engineering-related
|
Research Institution | Kumamoto University |
Principal Investigator |
ホサノ ハミド 熊本大学, 産業ナノマテリアル研究所, 教授 (00543406)
|
Co-Investigator(Kenkyū-buntansha) |
秀 拓一郎 北里大学, 医学部, 准教授 (40421820)
|
Project Period (FY) |
2021-04-01 – 2025-03-31
|
Project Status |
Granted (Fiscal Year 2024)
|
Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2024: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2023: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2022: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2021: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
|
Keywords | ワクチン/ドラッグデリバリー / マイクロフルイディクス / バイオエンジニアリング |
Outline of Research at the Start |
We will design, examine, and elucidate mechanisms/effectiveness of needleless, pain-free, inexpensive, small, controllable microjet vaccine/drug delivery systems. The main advantages are that they can be accurately controlled to deliver required amount of vaccine/drug to exact depth of dermis.
|
Outline of Annual Research Achievements |
The goal of the research for year 2022 (R 4) was defined as investigation of nanosecond-pulsed-electric-field induced cavitation/shock wave streaming microjet; quantitative evaluation of in-vitro and ex-vivo deliveries; and publication. According to the plan, electrodes with minimize erosion and appropriate nozzle configuration for nanosecond pulse discharge microjet delivery were designed and tested. The ultra-high-speed real-time highly magnified optical setup, which was constructed last year, was used to evaluate the microfluidic and flow physics of the electric discharge induced microstreaming for different applied energies. A manuscript from results has been prepared for submission to a high impact journal. Experiments were performed to evaluate microjet penetration depth and volume in ex-vivo vaccine/drug deliveries. Experiments have been continued to conjugate new protein nanoparticles to minimize the drug/vaccine volume, a new manuscript from the results has been prepared. For quantitative evaluation, in-vitro and ex-vivo microscopic visualization of microjets in skin, soft tissue, and tumor models were performed. In-vivo experiments were performed to understand effects of microjet and shock waves microstreaming on cells. The interesting results was published in an article, additional manuscript has been prepared and is under submission. Histological evaluations of ex-vivo samples have been underway.
|
Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
The research has been progressing according to the plan. The goals for the year 2022 (R 4) have been achieved.
|
Strategy for Future Research Activity |
Based on progress achieved during year 2022 (R 4), measures have been taken for the research to advance as planned. Further publication, international conference presentation, and international collaborations have been planned to advance the research.
|